Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease

BioFactors

Volumn 18, Issue 1-4, 2003, Pages 153-161

  Beal, M Flint ^a,d   Shults, Clifford W ^b,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; DIHYDROLIPOAMIDE DEHYDROGENASE; DIZOCILPINE; FRATAXIN; GLUTATHIONE REDUCTASE; ISOPRENE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUINONE DERIVATIVE; REMACEMIDE; THIOREDOXIN REDUCTASE; UBIDECARENONE; UBIQUINONE DERIVATIVE; DRUG DERIVATIVE; UBIQUINONE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG TOLERABILITY; ELECTRON TRANSPORT; FRIEDREICH ATAXIA; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; LIPID MEMBRANE; MITOCHONDRIAL MEMBRANE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; RAT; SIDE EFFECT; TISSUE DISTRIBUTION; ANIMAL; BLOOD; KINETICS; LIVER; METABOLISM; REVIEW;

ANIMALIA; ATAXIA;

ANIMALS; ANTIOXIDANTS; HUMANS; HUNTINGTON DISEASE; KINETICS; LIVER; PARKINSON DISEASE; UBIQUINONE;

EID: 0347419379     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520180218     Document Type: Conference Paper

References (57)

1. R.E. Bayer, An analysis of the role of coenzyme Q in free radical generation and as an antioxidant, Biochem Cell Biol 70 (1992), 390-403.
2. G. Dallner and P.J. Sindelar, Regulation of ubiquinone metabolism, Free Radic Biol Med 29 (2000), 285-294.
3. H. Noack, U. Kube and W. Augustin, Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria, Free Radic Res 20 (1994), 375-386.
4. 10 in man, Int. J Clin Pharmacol Ther Toxicol 24 (1986), 536-541.
5. T. Okamoto, T. Matsuya, Y. Fukunaga, T. Kishi and T. Yamagami, Human serum ubiquinol-10 levels and relationship to serum lipids, Int J Vitam Nutr Res 59 (1989), 288-292.
6. 10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation, Biochim Biophys Acta 1126 (1992), 247-254.
7. 10 formulations in healthy volunteers, Mol Aspects Med Suppl 15 (1994), s273-280.
8. 10: absorption, antioxidative properties, determinants and plasma levels, Free Radic Res 36 (2002), 389-397.
9. Y. Zhang, M. Turunen and E.-L. Appelkvist, Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of α-tocopherol into rat organs and cells, J Nutr 126 (1996), 2089-2097.
10. 10, Free Radic Biol Med 26 (1999), 1375-1382.
11. 10 and vitamin E alter the status of these compounds in rat tissues and mitochondria, J Nutr 130 (2000), 2343-2348.
12. M. Battino, A. Gorini, M.F. Villa, M.L. Genova, C. Bovina, S. Sassi, G.P. Littaru and G. Lenaz, Coenzyme Q content in synaptic and non-synaptic mitochondria from different brain regions in the ageing rat, Mech Ageing Dev 78 (1995), 173-187.
13. R.E. Beyer, B.-A. Burnett, K.J. Cartwright, D.E. Edington, M.J. Falzon, K.R. Kreitman, T.W. Kuhn, B.J. Ramp, S.Y.S. Rhee, M.J. Rosenwasser, M. Stein and L.C.-I. An, Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat, Mech Ageing Dev 32 (1985), 267-281.
14. A. Kalen, E.-L. Appelkvist and G. Daliner, Age-related changes in the lipid compositions of rat and human tissues, Lipids 24 (1989), 579-584.
15. 10 administration increases rain mitochondrial concentrations and exerts neuroprotective effects, Proc. Natl. Acad Sci USA 95 (1998), 8892-8897.
16. 10 administration on its tissue concentrations, mitochondrial oxidant generation and oxidative stress in the rat, Free Radic Biol Med 33 (2002), 627-638.
17. M. Bentinger, G. Dallner, T. Chojnacki and E. Swiezewska, Distribution and breakdown of labeled coenzyme Q (10) in rat, Free Radic Biol Med 34 (2003), 563-575.
18. V. Kagan, E. Serbinova and L. Packer, Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling, Biochem Biophys Res Commun 169 (1990), 851-857.
19. J.J. Poderoso, M.C. Carreras, F. Schopfer, C.L. Lisdero, N.A. Riobo, C. Giulivi, A.D. Boveris, A. Boveris and E. Cadenas, The reaction of nitirc oxide with ubiquinol: kinetic properties and biological significance, Free Radic Biol Med 26 (1999), 925-935.
20. V.E. Kagan, E.A. Serbinova, G.M. Koynova, S.A. Kitanova, V.A. Tyurin, T.S. Stoytchev, P.J. Quinn, L. Packer, Antioxidant action of ubiquinol homologues with different isoprenoid chain length in biomembranes, Free Radic Biol Med 9 (1990), 117-126.
21. J.J. Maguire, V. Kagan, B.A. Ackrell, E. Serbinova and L. Packer, Succinate-ubiquinone reductase linked recycling of α-tocopherol in reconstituted systems and mitochondria: requirement of reduced ubiquinone, Arch Biochem 292 (1992), 47-53.
22. K. Mukai, H. Morimoto, S. Kikuchi and S. Nagaoka, Kinetic study of free-radical-scavenging action of biological hydroquinones (reduced forms of ubiquinone, vitamin K and tocopherol quinone) in solution, Biochim Biophys Acta 157 (1993), 313-317.
23. H. Shi, N. Noguchi and E. Niki, Comparative study on dynamics of antioxidative action of α-tocopheryl hydroquinone, ubiquinol, and α-tocopherol against lipid peroxidation, Free Radic Biol Med 27 (1999), 334-346.
24. A.V. Kozlov, L. Gille, K. Staniek and H. Nohl, Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone, Arch Biochem Biophys 363 (1999), 148-154.
25. 10 in mice treated with 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine and diethyldithiocarbamate, Eur J Pharmacol 266 (1994), 291-300.
26. 10 inhibits atherosclerosis in apolipoprotein E gene knockout mice, Arterioscler Thromb Vasc. Biol 21 (2001), 585-593.
27. 10 enrichment decreases oxidative DNA damage in human lymphocytes, Free Radic Bio Med 27 (1999), 1027-1032.
28. K.S. Echtay, E. Winkler and M. Klingenberg, Coenzyme Q is an obligatory cofactor for uncoupling protein function, Nature 408 (2000), 609-613.
29. K. Echtay, E. Winkler, K. Frischmuth and M. Klingenberg, Uncoupling protein 2 and 3 are highly active H+ transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone), Proc Natl Acad Sci USA 98 (2001), 1416-1421.
30. D. Ricquier and F. Bouillaud, The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP, Biochem J 345 (2000), 161-179.
31. P.G. Sullivan, C. Dube, K. Dorenbos, O. Steward and T.Z. Baram, Mitochondrial uncoupling protein-2 protects the immature brain from excitotxic neuronal death, Ann Neurology (2003) published online.
32. L. Walter, V. Nogueira, X. Leverve, M.P. Heitz, P. Bernardi and E. Fontaine, Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site, J Biol Chem 275 (2000), 29521-29527.
33. E. Fontaine, F. Ichas and P. Bernardi, A ubiquinone-binding site regulates the mitochondrial permeability transition pore, J Biol Chem 273 (1998), 25734-25740.
34. S. Vadhanavikit and H.E. Ganther, Decreased ubiquinone levels in tissues of rats deficient in selenium, Biochem Biophys Res Comm 190 (1993), 921-926.
35. S. Vadhanavikit and H.E. Ganther, Selenium deficiency and decreased coenzyme Q levels, Molec Aspects Med 15 (1994), s103-s107.
36. L. Xia, T. Nordman, J.M. Olsson, A. Damdimopoulos, L. Bjorkhem-Bergman, I. Nalvarte, L.C. Eriksson, E.S. Arner, G. Spurou and M. Bjornstedt, The mammalian cystolic selenoenzyme thioredoxin reductase reduces ubiquinone, A novel mechanism for defense against oxidative stress, J Biol Chem 278 (2003), 2141-2146.
37. J.M. Olsson, L. Xia, L.C. Eriksson and M. Bjornstedt, Ubiquinone is reduced by lipoamide dehydrogenase and this reaction is potently stimulated by zinc, FEBS Lett 448 (1999), 190-192.
38. L. Xia, M. Bjornstedt, T. Nordman, L.C. Eriksson and J.M. Olsson, Reduction of ubiquinone by lipoamide dehydrogenase, Eur J Biochem 268 (2001), 1486-1490.
39. R.E. Beyer, J. Segura-Aguilar, S. Di Bernardo, M. Cavazzoni, R. Fato, D. Fiorentini, M.C. Galli, M. Setti, L. Landi and G. Lenaz, The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems, Proc Natl Acad Sci USA 93 (1986), 2528-2532.
40. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate, Annals Neurol 36 (1994), 882-888.
41. 10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice, Brain Res 783 (1998), 109-114.
42. 10, Neurosci Lett 177 (1994), 58-62.
43. M.F. Beal, E. Brouillet, B.G. Jenkins, R.J. Ferrante, N.W. Kowall, J.M. Miller, E. Storey, R. Srivastava, B.R. Rosen and B.T. Hyman, Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid, J Neurosci 13 (1993), 4181-4192.
44. E. Brouillet, P. Hantraye, R.J. Ferrante, R. Dolan, A. Leroy-Willig, N.W. Kowall and M.F. Beal, Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates, Proc Natl Acad Sci USA 92 (1995), 7105-7109.
45. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies and G.P. Bates, Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell 87 (1996), 493-506.
46. 10 and remacemide in transgenic mouse models of Huntington's disease, J Neurosci 22 (2002), 1592-1599.
47. 10 tolerability in Huntington's Disease, Annals Neurol 41 (1997), 160-165.
48. 10 tolerability in Huntington's Disease, Mov Disorders 11 (1996), 321-323.
49. 10 and remacemide in Huntington's disease, Neurology 57 (2001), 375-376.
50. H. Braak and E. Braak, Pathoanatomy of Parkinson's Disease, J. Neurol 247 (2000) 2:II3-10.
51. J. W. Langston, P. Ballard, J. W. Tetrud and I. Irwin, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis, Science 219 (1983), 979-980.
52. S. Przedborski and V. Jackson-Lewis, Mechanisms of MPTP toxicity, Mov. Disord. 13 (1998), 35-38.
53. A.H.V. Schapira, V. M. Mann, J.M. Cooper, D. Dexter, S.E. Daniel, P. Jenner, J.B. Clark and C.D.J. Marsden, Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's Disease, J. Neurochem. 55 (1990), 2142-2145.
54. R. Haas, F. Nasirian, K. Nakano, D. Ward, M. Pay, R. Hill and C.W. Shults, Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's Disease, Ann. Neurol. 37 (1995), 714-772.
55. 10 is reduced in mitochondria from parkinsonian patients, Ann Neurol 42 (1997), 261-264.
56. 10 in parkinsonian patients, Neurology 50 (1998), 793-795.
57. 10 in early Parkinson's disease: evidence of slowing of the functional decline, Arch. Neurol. 59 (2002), 1541-1550.